tbuckley/cabot-search huggingface dataset:
Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry
Authors: Andrea Chiricozzi, Marina Talamonti, Clara De Simone, Marco Galluzzo, Niccolò Gori, Gabriella Fabbrocini, Angelo Valerio Marzano, Giampiero Girolomoni, Annamaria Offidani, Maria Teresa Rossi, Luca Bianchi, Antonio Cristaudo, Maria Teresa Fierro, Luca Stingeni, Giovanni Pellacani, Giuseppe Argenziano, Annalisa Patrizi, Paolo Pigatto, Marco Romanelli, Paola Savoia, Pietro Rubegni, Caterina Foti, Nicola Milanesi, Anna Belloni Fortina, Maria Rita Bongiorno, Teresa Grieco, Sergio Di Nuzzo, Maria Concetta Fargnoli, Andrea Carugno, Alberico Motolese, Franco Rongioletti, Paolo Amerio, Riccardo Balestri, Concetta Potenza, Giuseppe Micali, Cataldo Patruno, Iris Zalaudek, Maurizio Lombardo, Claudio Feliciani, Lucia Di Nardo, Fabrizio Guarneri, Ketty Peris
Journal: Allergy (2021)

Abstract Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician‐ and patient‐reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS‐CoV‐2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID‐related death occurred. Conclusions Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab‐treated patients.
Decline in COVID-19 Hospitalization Growth Rates Associated with Statewide Mask Mandates — 10 States, March–October 2020
Authors: Heesoo Joo, Gabrielle F. Miller, Gregory Sunshine, Maxim Gakh, Jamison Pike, Fiona P. Havers, Lindsay Kim, Regen Weber, Sebnem Dugmeoglu, Christina Watson, Fátima Coronado
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), is transmitted predominantly by respiratory droplets generated when infected persons cough, sneeze, spit, sing, talk, or breathe. CDC recommends community use of face masks to prevent transmission of SARS-CoV-2 (1). As of October 22, 2020, statewide mask mandates were in effect in 33 states and the District of Columbia (2). This study examined whether implementation of statewide mask mandates was associated with COVID-19-associated hospitalization growth rates among different age groups in 10 sites participating in the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) in states that issued statewide mask mandates during March 1-October 17, 2020. Regression analysis demonstrated that weekly hospitalization growth rates declined by 2.9 percentage points (95% confidence interval [CI] = 0.3-5.5) among adults aged 40-64 years during the first 2 weeks after implementing statewide mask mandates. After mask mandates had been implemented for ≥3 weeks, hospitalization growth rates declined by 5.5 percentage points among persons aged 18-39 years (95% CI = 0.6-10.4) and those aged 40-64 years (95% CI = 0.8-10.2). Statewide mask mandates might be associated with reductions in SARS-CoV-2 transmission and might contribute to reductions in COVID-19 hospitalization growth rates, compared with growth rates during <4 weeks before implementation of the mandate and the implementation week. Mask-wearing is a component of a multipronged strategy to decrease exposure to and transmission of SARS-CoV-2 and reduce strain on the health care system, with likely direct effects on COVID-19 morbidity and associated mortality.
The VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells
Authors: Jérémy Lagrange, Morel E Worou, Jean-Baptiste Michel, Alexandre Raoul, Mélusine Didelot, Vincent Muczynski, Paulette Legendre, François Plénat, Guillaume Gauchotte, Marc-Damien Lourenco-Rodrigues, Olivier D Christophe, Peter J Lenting, Patrick Lacolley, Cécile V Denis, Véronique Regnault
Journal: Cardiovascular Research (2021)

Von Willebrand factor (VWF) is a plasma glycoprotein involved in primary haemostasis, while also having additional roles beyond haemostasis namely in cancer, inflammation, angiogenesis, and potentially in vascular smooth muscle cell (VSMC) proliferation. Here, we addressed how VWF modulates VSMC proliferation and investigated the underlying molecular pathways and the in vivo pathophysiological relevance.
A systemic inflammatory response involving C-Reactive Protein, Interleukin-6, Interleukin-8 and Tumor Necrosis Factor-alpha contributes to the development of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.
Authors: Henri Schots, Ivan Van Riet, Tarek Ben Otman, Marc De Waele, Benjamin Van Camp
Journal: Blood (2001)
De Novo Colorectal and Pancreatic Cancer in Liver‐Transplant Recipients: Identifying the Higher‐Risk Populations
Authors: Navine Nasser‐Ghodsi, Kristin Mara, Kymberly D. Watt
Journal: Hepatology (2021)

Gastrointestinal (GI) malignancies are common after liver transplantation. The aim of this study was to identify the risk and timing of the more common GI malignancies, colorectal and pancreatic cancer, to aid in optimizing potential posttransplant screening practices.Data from the United Network for Organ Sharing database of all adult liver-transplant recipients from 1997 to 2017 were analyzed and a comparison made with cancer incidence from general population data using Surveillance, Epidemiology, and End Results data. Of 866 de novo GI malignancies, 405 colorectal and 216 pancreas were identified. The highest cumulative incidence for colorectal cancer occurred in recipients with primary sclerosing cholangitis (PSC), recipients over the age of 50 with non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC)/cholangiocarcinoma (CCA), and females >50 years with alcohol-associated liver disease and HCC/CCA, with risk increasing above the general population within 5 years of transplant. Patients with PSC and HCC/CCA or NASH and HCC/CCA have the highest cumulative incidence of pancreatic cancer also rising within 5 years following transplant, with those patients >50 years old conferring the highest risk.These data identify a high-risk cohort that warrants consideration for intensified individualized screening practices for colorectal cancer after liver transplantation. In addition to recipients with PSC, further study of recipients with NASH and HCC/CCA and females with alcohol-associated liver disease and HCC/CCA may be better tailored to colorectal cancer screening ideals. Higher-risk patient populations for pancreatic cancer (PSC and NASH with HCC/CCA) would benefit from further study to determine potential screening practices. GI malignancies occur at higher rates in liver-transplant patients compared with the general population. In the era of individualized medicine, this study identifies the highest-risk transplant recipients (PSC and NASH cirrhosis with coexisting HCC/CCA) who may benefit from altered screening practices for these malignancies.
Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis
Authors: John H. Lockhart, Jeffrey VanWye, Richa Banerjee, Samuel A. Wickline, Hua Pan, Hana Totary-Jain
Journal: Molecular Therapy (2021)

Cardiovascular disease is the leading cause of death and disability worldwide. Effective delivery of cell-selective therapies that target atherosclerotic plaques and neointimal growth while sparing the endothelium remains the Achilles heel of percutaneous interventions. The current study utilizes synthetic microRNA switch therapy that self-assembles to form a compacted, nuclease-resistant nanoparticle <200 nM in size when mixed with cationic amphipathic cell-penetrating peptide (p5RHH). These nanoparticles possess intrinsic endosomolytic activity that requires endosomal acidification. When administered in a femoral artery wire injury mouse model in vivo, the mRNA-p5RHH nanoparticles deliver their payload specifically to the regions of endothelial denudation and not to the lungs, liver, kidney, or spleen. Moreover, repeated administration of nanoparticles containing a microRNA switch, consisting of synthetically modified mRNA encoding for the cyclin-dependent kinase inhibitor p27Kip1 that contains one complementary target sequence of the endothelial cell-specific miR-126 at its 5' UTR, drastically reduced neointima formation after wire injury and allowed for vessel reendothelialization. This cell-selective nanotherapy is a valuable tool that has the potential to advance the fight against neointimal hyperplasia and atherosclerosis.
Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy
Authors: Max J. Karlsson, Fernanda Costa Svedman, Abdellah Tebani, David Kotol, Veronica Höiom, Linn Fagerberg, Fredrik Edfors, Mathias Uhlén, Suzanne Egyhazi Brage, Gianluca Maddalo
Journal: Cancer Research (2021)

Abstract Malignant cutaneous melanoma is one of the most common cancers in young adults. During the last decade, targeted and immunotherapies have significantly increased the overall survival of patients with malignant cutaneous melanoma. Nevertheless, disease progression is common, and a lack of predictive biomarkers of patient response to therapy hinders individualized treatment strategies. To address this issue, we performed a longitudinal study using an unbiased proteomics approach to identify and quantify proteins in plasma both before and during treatment from 109 patients treated with either targeted or immunotherapy. Linear modeling and machine learning approaches identified 43 potential prognostic and predictive biomarkers. A reverse correlation between apolipoproteins and proteins related to inflammation was observed. In the immunotherapy group, patients with low pretreatment expression of apolipoproteins and high expression of inflammation markers had shorter progression-free survival. Similarly, increased expression of LDHB during treatment elicited a significant impact on response to immunotherapy. Overall, we identified potential common and treatment-specific biomarkers in malignant cutaneous melanoma, paving the way for clinical use of these biomarkers following validation on a larger cohort. Significance: This study identifies a potential biomarker panel that could improve the selection of therapy for patients with cutaneous melanoma.
Mechanisms of Congenital Heart Disease Caused by NAA15 Haploinsufficiency
Authors: Tarsha Ward, Warren Tai, Sarah Morton, Francis Impens, Petra Van Damme, Delphi Van Haver, Evy Timmerman, Gabriela Venturini, Kehan Zhang, Min Young Jang, Jon A.L. Willcox, Alireza Haghighi, Bruce D. Gelb, Wendy K. Chung, Elizabeth Goldmuntz, George A. Porter, Richard P. Lifton, Martina Brueckner, H. Joseph Yost, Benoit G. Bruneau, Joshua Gorham, Yuri Kim, Alexandre Pereira, Jason Homsy, Craig C. Benson, Steven R. DePalma, Sylvia Varland, Christopher S. Chen, Thomas Arnesen, Kris Gevaert, Christine Seidman, J.G. Seidman
Journal: Circulation Research (2021)

[Figure: see text].
Pharmacokinetics Of Indacaterol/Mometasone Furoate In Healthy Chinese Volunteers: Results From A Randomized, Open-label, Parallel-group Study
Authors: Yun Liu, Weie Cao, Yijun Wang, Soniya Vaidya, Jian Sun, Yingying Wang, Hanns-Christian Tillmann, Chenyu Qian
Journal: Journal of Allergy and Clinical Immunology (2021)
Abstract 1446: Role of the Conserved Acidic N-terminus of Cardiac Troponin I in Regulating Myocardial Function
Authors: Sakthivel Sadayappan, Jack W Howarth, Hanna Osinska, Raisa Klevitsky, John N Lorenz, Paul R Rosevear, Jeffrey Robbins
Journal: Circulation (2006)

Background: Cardiac Troponin I (cTnI) phosphorylation plays a major role in regulating myocardial contractility and relaxation during β-adrenergic stimulation. The role of the conserved acidic N-te...
E-cadherin is regulated by GATA-2 and marks the early commitment of mouse hematopoietic progenitors to the basophil and mast cell fates
Authors: Anaïs Wanet, Mahmoud A. Bassal, Sweta B. Patel, Francisco Marchi, Samanta A. Mariani, Nouraiz Ahmed, Haoran Zhang, Marta Borchiellini, Sisi Chen, Junyan Zhang, Annalisa Di Ruscio, Kensuke Miyake, Mindy Tsai, Anuya Paranjape, Shin-Young Park, Hajime Karasuyama, Timm Schroeder, Elaine Dzierzak, Stephen J. Galli, Daniel G. Tenen, Robert S. Welner
Journal: Science Immunology (2021)

E-cadherin expression on mouse hematopoietic progenitors marks their commitment to the basophil and mast cell fates at an early stage.
Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity
Authors: Niels Heemskerk, Mandy Gruijs, A. Robin Temming, Marieke H. Heineke, Dennis Y. Gout, Tessa Hellingman, Cornelis W. Tuk, Paula J. Winter, Suzanne Lissenberg-Thunnissen, Arthur E.H. Bentlage, Marco de Donatis, Marijn Bögels, Thies Rösner, Thomas Valerius, Jantine E. Bakema, Gestur Vidarsson, Marjolein van Egmond
Journal: Journal of Clinical Investigation (2021)

Most clinically used anticancer mAbs are of the IgG isotype, which can eliminate tumor cells through NK cell–mediated antibody-dependent cellular cytotoxicity and macrophage-mediated antibody-dependent phagocytosis. IgG, however, ineffectively recruits neutrophils as effector cells. IgA mAbs induce migration and activation of neutrophils through the IgA Fc receptor (FcαRI) but are unable to activate NK cells and have poorer half-life. Here, we combined the agonistic activity of IgG mAbs and FcαRI targeting in a therapeutic bispecific antibody format. The resulting TrisomAb molecules recruited NK cells, macrophages, and neutrophils as effector cells for eradication of tumor cells in vitro and in vivo. Moreover, TrisomAb had long in vivo half-life and strongly decreased B16F10gp75 tumor outgrowth in mice. Importantly, neutrophils of colorectal cancer patients effectively eliminated tumor cells in the presence of anti-EGFR TrisomAb but were less efficient in mediating killing in the presence of IgG anti-EGFR mAb (cetuximab). The clinical application of TrisomAb may provide potential alternatives for cancer patients who do not benefit from current IgG mAb therapy.
Contact dermatitis associated with preservatives: Retrospective analysis of North American Contact Dermatitis Group data, 1994 through 2016
Authors: Amber Reck Atwater, Amy J. Petty, Beiyu Liu, Cynthia L. Green, Jonathan I. Silverberg, Joel G. DeKoven, Donald V. Belsito, Margo J. Reeder, Denis Sasseville, James S. Taylor, Howard I. Maibach, Matthew J. Zirwas, James G. Marks, Kathryn A. Zug, Joseph F. Fowler, Melanie D. Pratt, Vincent A. DeLeo, Erin M. Warshaw
Journal: Journal of the American Academy of Dermatology (2021)
About the recommendation of the GINA strategy report on asthma step 1
Authors: Serena Ferretti, Mariannita Gelsomino, Stefano Miceli Sopo
Journal: European Respiratory Journal (2021)

<b>There is not yet sufficient evidence to transfer the use of as-needed low dose ICS–formoterol, as GINA has recommended since 2019, instead of as-needed SABA to patients affected by step 1 asthma</b>https://bit.ly/2G1IieN
Abstract 10762: Relationship of Hdl-associated Cholesterol Efflux Capacity to Coronary Collateralization In Diabetic and Non-diabetic Patients With Stable Angina and Chronic Total Occlusion
Authors: Xiao Qun Wang, Ying Shen, Jia Wei Chen, Xin Yi Shu, Chang Li, Chen Die Yang, Lin Lu, Feng Hua Ding, Zhen Kun Yang, Rui Yan Zhang, Wei Feng Shen
Journal: Circulation (2019)

Introduction: High-density lipoprotein (HDL) functional capacity is markedly impaired in patients with diabetes. The role of HDL in maintaining coronary collateralization in diabetic and non-diabet...
Radiotherapy Remains Underused in the Treatment of Soft-Tissue Sarcomas: Disparities in Practice Patterns in the United States
Authors: Vishruth K. Reddy, Varsha Jain, Sriram Venigalla, William P. Levin, Robert J. Wilson, Kristy L. Weber, Anusha Kalbasi, Ronnie A. Sebro, Jacob E. Shabason
Journal: Journal of the National Comprehensive Cancer Network (2021)

Background: Practice patterns of radiation therapy (RT) use for soft-tissue sarcoma (STS) remain quite variable, despite clinical practice guidelines recommending the addition of RT to surgery for patients with high-grade STS, particularly for larger tumors. Using the National Cancer Database (NCDB), we assessed patterns of overall RT use, neoadjuvant versus adjuvant treatment, and specific RT modalities in this population. Patients and Methods: Patients aged ≥18 years with stage II/III STS in 2004 through 2015 were identified from the NCDB. Patterns of care were assessed using multivariable logistic regression analysis. Results: Of 27,426 total patients, 11,654 (42%) were treated with surgery alone versus 15,772 (58%) with RT in addition to surgery, with no overall increase in RT use over the study period. Notable clinical predictors of receipt of RT included tumor size (&gt;5 cm), grade III, and tumors arising in the extremities. Conversely, female sex, older age (≥70 years), Black race, noncommercial insurance coverage, farther distance to treatment, and poor performance status were negative predictors of RT use. Of those receiving RT, 27% were treated with neoadjuvant RT and 73% with adjuvant RT. The proportion of those receiving neoadjuvant RT increased over time. Relevant factors associated with neoadjuvant RT included treatment at academic centers, larger tumor size, and extremity tumors. Of those who received RT with a modality specified as either intensity-modulated RT (IMRT) or 3D conformal RT (3DCRT), 61% were treated with IMRT and 39% with 3DCRT. The proportion of patients treated with IMRT increased over time. Relevant factors associated with IMRT use included treatment at academic centers, commercial insurance coverage, and larger and nonextremity tumors. Conclusions: Although use of neoadjuvant RT and IMRT has increased over time, a significant number of patients with STS are not receiving adjuvant or neoadjuvant RT. Our findings also note potential sociodemographic disparities and highlight the concern that not all patients with STS are being equally considered for RT.
Pulmonary Cavitation: A Hint of <i>Ralstonia mannitolilytica</i> Infection through Imaging
Authors: Peng Xie, Jiaji Liu, Liu Wu, Daishun Liu
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

"Pulmonary Cavitation: A Hint of Ralstonia mannitolilytica Infection through Imaging." American Journal of Respiratory and Critical Care Medicine, 203(12), pp. 1569–1570
Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines
Authors: Oluwaseun Egunsola, Fiona Clement, John Taplin, Liza Mastikhina, Joyce W. Li, Diane L. Lorenzetti, Laura E. Dowsett, Tom Noseworthy
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Low-dose intradermal influenza vaccines could be a suitable alternative to full intramuscular dose during vaccine shortages. <h3>Objective</h3> To compare the immunogenicity and safety of the influenza vaccine at reduced or full intradermal doses with full intramuscular doses to inform policy design in the event of vaccine shortages. <h3>Data Sources</h3> MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched for studies published from 2010 until June 5, 2020. <h3>Study Selection</h3> All comparative studies across all ages assessing the immunogenicity or safety of intradermal and intramuscular influenza vaccinations were included. <h3>Data Extraction and Synthesis</h3> Data were extracted by a single reviewer and verified by a second reviewer. Discrepancies between reviewers were resolved through consensus. Random-effects meta-analysis was conducted. <h3>Main Outcomes and Measures</h3> Primary outcomes included geometric mean titer, seroconversion, seroprotection, and adverse events. <h3>Results</h3> A total of 30 relevant studies were included; 29 studies were randomized clinical trials with 13 759 total participants, and 1 study was a cohort study of 164 021 participants. There was no statistically significant difference in seroconversion rates between the 3-µg, 6-µg, 7.5-µg, and 9-µg intradermal vaccine doses and the 15-µg intramuscular vaccine dose for each of the H1N1, H3N2, and B strains, but rates were significantly higher with the 15-µg intradermal dose compared with the 15-µg intramuscular dose for the H1N1 strain (rate ratio [RR], 1.10; 95% CI, 1.01-1.20) and B strain (RR, 1.40; 95% CI, 1.13-1.73). Seroprotection rates for the 9-µg and 15-µg intradermal doses did not vary significantly compared with the 15-µg intramuscular dose for all the 3 strains, except for the 15-µg intradermal dose for the H1N1 strain, for which rates were significantly higher (RR, 1.05; 95% CI, 1.01-1.09). Local adverse events were significantly higher with intradermal doses than with the 15-µg intramuscular dose, particularly erythema (3-µg dose: RR, 9.62; 95% CI, 1.07-86.56; 6-µg dose: RR, 23.79; 95% CI, 14.42-39.23; 9-µg dose: RR, 4.56; 95% CI, 3.05-6.82; 15-µg dose: RR, 3.68; 95% CI, 3.19-4.25) and swelling (3-µg dose: RR, 20.16; 95% CI, 4.68-86.82; 9-µg dose: RR, 5.23; 95% CI, 3.58-7.62; 15-µg dose: RR, 3.47 ; 95% CI, 2.21-5.45). Fever and chills were significantly more common with the 9-µg intradermal dose than the 15-µg intramuscular dose (fever: RR, 1.36; 95% CI, 1.03-1.80; chills: RR, 1.24; 95% CI, 1.03-1.50) while all other systemic adverse events were not statistically significant for all other doses. <h3>Conclusions and Relevance</h3> These findings suggest that reduced-dose intradermal influenza vaccination could be a reasonable alternative to standard dose intramuscular vaccination.
Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate
Authors: Fan-En Kong, Guang-Meng Li, Yun-Qiang Tang, Shao-Yan Xi, Jane Ho Chun Loong, Mei-Mei Li, Hao-Long Li, Wei Cheng, Wen-Jie Zhu, Jia-Qiang Mo, Yuan-Feng Gong, Hui Tang, Yue Zhao, Yan Zhang, Stephanie Ma, Xin-Yuan Guan, Ning-Fang Ma, Mao-Bin Xie, Ming Liu
Journal: Science Translational Medicine (2021)

CLDN6 is not only a marker of hepatocellular carcinoma but also a therapeutic target by promoting sorafenib resistance and lineage plasticity.